Startek - SRT Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Startek in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRT shares.
View SRT analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price targets for Startek's stock. Their SRT share price forecasts range from $5.50 to $6.00. On average, they predict the company's share price to reach $5.75 in the next year. This suggests a possible upside of 55.8% from the stock's current price.
View analysts price targets for SRT or view top-rated stocks among Wall Street analysts.

Startek's stock was trading at $5.22 at the start of the year. Since then, SRT stock has decreased by 29.3% and is now trading at $3.69.
View the best growth stocks for 2022 here.

Startek saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 37,300 shares, a decline of 49.6% from the October 31st total of 74,000 shares. Based on an average daily volume of 53,200 shares, the short-interest ratio is currently 0.7 days. Approximately 0.4% of the company's stock are sold short.
View Startek's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our SRT earnings forecast.

Startek, Inc. (NYSE:SRT) issued its earnings results on Tuesday, November, 2nd. The business services provider reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.03. The business services provider had revenue of $172.79 million for the quarter, compared to the consensus estimate of $162.31 million. Startek had a net margin of 1.09% and a trailing twelve-month return on equity of 5.55%. During the same quarter in the prior year, the firm posted $0.01 EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Startek investors own include Amicus Therapeutics (FOLD), KeyCorp (KEY), SentinelOne (S), Vishay Intertechnology (VSH), Huntington Bancshares (HBAN), Kindred Biosciences (KIN), Mitek Systems (MITK), People's United Financial (PBCT), Pfizer (PFE) and Primo Water (PRMW).

Startek trades on the New York Stock Exchange (NYSE) under the ticker symbol "SRT."

Startek's stock is owned by a variety of retail and institutional investors. Top institutional investors include Beryl Capital Management LLC (2.17%), Dimensional Fund Advisors LP (1.79%), Renaissance Technologies LLC (1.47%), Vanguard Group Inc. (1.33%), BlackRock Inc. (0.76%) and Boothbay Fund Management LLC (0.30%). Insiders that own company stock include Albert Aboody, Aparup Sengupta, Csp Management Ltd, Mukesh Sharda and Sudip Banerjee.
View institutional ownership trends.

Shares of SRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRT stock can currently be purchased for approximately $3.69.

Startek (NYSE:SRT) has a market capitalization of $148.63 million and generates $703.63 million in revenue each year. The business services provider earns $1.50 million in net income (profit) each year or $0.18 on an earnings per share basis.

The company employs 45,000 workers across the globe.

Startek's mailing address is 6200 SOUTH SYRACUSE WAY SUITE 485, GREENWOOD VILLAGE CO, 80111. The official website for the company is www.startek.com. The business services provider can be reached via phone at (303) 262-4500, via email at investor@startek.com, or via fax at 302-655-5049.